Driehaus Capital Management Reduces $2M in Xenon Pharmaceuticals Inc. ($XENE)
Driehaus Capital trims its holdings in Xenon Pharmaceuticals by 47,038 shares, reflecting a 1% reduction.
Key Points
- Driehaus Capital Management trimmed its stake in Xenon Pharmaceuticals by 47,038 shares, now holding 4,491,653 shares worth $234 million.
- Xenon Pharmaceuticals, trading at $52.10, has a market cap of $5.04 billion and a forward P/E ratio indicating no current profitability.
- Insider activity includes planned sales and buys by executives, while analysts maintain a strong buy consensus with targets up to $100.
In its latest filing with the SEC, Driehaus Capital Management reported trimming its position in Xenon Pharmaceuticals Inc. (NasdaqGM: XENE). The fund reduced its holdings by 47,038 shares, bringing its total stake to 4,491,653 shares valued at approximately $234 million as of the reporting period.
What Changed in Driehaus Capital's Xenon Pharmaceuticals Position
Driehaus Capital Management decreased its stake in Xenon Pharmaceuticals by 47,038 shares, representing a 1% reduction. Prior to this adjustment, the fund held 4,538,691 shares. The firm's current position is valued at around $234 million.
Other Institutional Activity in Xenon Pharmaceuticals
FMR LLC significantly boosted its stake in Xenon Pharmaceuticals, adding 1,898,241 shares to hold a total of 10,818,491 shares worth about $629 million. AVORO Capital Advisors LLC increased its holdings by 353,333 shares, ending with 5,777,777 shares valued at $336 million. BlackRock, Inc. also grew its position by 539,834 shares, reaching a total of 5,640,118 shares worth approximately $328 million. Wellington Management Group LLP made a smaller addition, increasing its stake by 64,862 shares to 4,829,641 shares, valued at $281 million. Meanwhile, Polar Capital Holdings PLC made a notable increase of 1,939,618 shares, bringing its total to 4,405,312 shares valued at $256 million.
Xenon Pharmaceuticals Stock Snapshot
Shares of Xenon Pharmaceuticals (NasdaqGM: XENE) are currently trading near $52.10. The company has a market capitalization of approximately $5.04 billion. With a forward P/E ratio of -10.4, the company is not currently profitable. Its stock has experienced a 52-week range between $30.00 and $63.95. The 50-day moving average is $55.46, and the 200-day moving average is $46.17. Xenon Pharmaceuticals maintains strong liquidity with a current ratio of 27.79 and a quick ratio of 27.53, alongside a debt-to-equity ratio of 0.56.
Recent Earnings
Xenon Pharmaceuticals reported a net margin of 0.0% and a return on equity of -37.53%. While the company is not currently profitable, it continues to develop its pipeline. The next earnings report is expected on August 10, 2026.
Insider Buying and Selling at Xenon Pharmaceuticals Inc.
Recent insider activity at Xenon Pharmaceuticals includes planned sales and purchases by company executives. On June 5, 2026, Gillian Cannon sold 1,190 shares at an average price of $53.14 under a planned transaction. Similarly, Gary Patou sold 1,322 shares on the same date. Earlier, on June 3, 2026, Patou, along with Patrick Machado and Steven Gannon, purchased shares in unplanned transactions.
Analysts Set New Price Targets
On May 27, 2026, JP Morgan maintained its 'buy' rating on Xenon Pharmaceuticals with a price target of $82. RBC Capital and Needham also maintained 'buy' ratings on May 8, 2026, with targets of $82 and $78, respectively. The consensus among 19 analysts is a 'strong buy', with a mean target price of $80.56.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Burnaby, British Columbia. It focuses on neuroscience, discovering and developing treatments for neurological and psychiatric disorders. Its lead product candidates include Azetukalner, a novel potassium channel opener in Phase 3 trials for epilepsy and neuropsychiatric disorders. Founded in 1996, the company collaborates with Neurocrine Biosciences to develop new therapies for epilepsy.
Bottom Line
Driehaus Capital Management's slight reduction in its Xenon Pharmaceuticals stake reflects the dynamic nature of institutional investments. Investors track such filings to gauge fund sentiment and potential future moves. As always, keep in mind that 13F filings are historical and may not reflect current positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.